Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 12/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 12/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 12/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 12/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 12/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 12/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 12/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754773 | 0.89 | HDAC6 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL753773 | 0.87 | HDAC3 (0.47) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL753793 | 0.87 | HDAC6 (0.63) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL755955 | 0.82 | HDAC1 (0.60) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL763165 | 0.79 | HDAC3 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL753775 | 0.79 | HDAC3 (0.76) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12295642 | 0.78 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL756327 | 0.77 | HDAC3 (0.75) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL754643 | 0.76 | HDAC6 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12295717 | 0.75 | HDAC3 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885710-B1 | SUBSTITUTED AMINOPROPENYL PIPERIDINE OR MORPHOLINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-19 | — | — | EP | disclosed |
| US-8377935-B2 | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-8377935-B2 | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-20120157456-A1 | SUBSTITUTED AMINOPROPENYL PIPERIDINE OR MORPHOLINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157456-A1 | SUBSTITUTED AMINOPROPENYL PIPERIDINE OR MORPHOLINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-21 | — | — | US | disclosed |
| US-8138198-B2 | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase | ANGIBAUD PATRICK RENE (FR) | 2012-03-20 | — | — | US | disclosed |
| US-8138198-B2 | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase | ANGIBAUD PATRICK RENE (FR) | 2012-03-20 | — | — | US | disclosed |
| US-20090221580-A1 | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase | ANGIBAUD PATRICK RENE | 2009-09-03 | — | — | US | disclosed |
| US-20090221580-A1 | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase | ANGIBAUD PATRICK RENE | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221580-A1 | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC3 | HDAC3 3/4885HDAC4 8/4885HDAC1 1/4885 |
| US-20120157456-A1 | SUBSTITUTED AMINOPROPENYL PIPERIDINE OR MORPHOLINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC2, HDAC3 | HDAC3 3/4885HDAC4 8/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.